HOME  >  R&D

Oncolytic virus

Oncolytic virus

Recent breakthroughs in targeted cancer therapeutics and cancer immunotherapy have become a promising treatment strategy for cancer patients who respond poorly to conventional cancer therapies. Despite their relative success, tumor recurrence and metastasis are eventually observed even in patients who initially responded well to targeted therapeutics. The major limitation of currently commercialized cancer immunotherapeutics is that only a small subset of patients show good response toward immunotherapy. These apparent limitations in advanced cancer therapeutics necessitate the development of novel therapeutics that can address these unmet needs of cancer patients.

To this end, the oncolytic virus, which replicates and selectively destroys cancer cells, can be a promising alternative. Importantly, oncolytic virus-mediated destruction of cancer cells induces a systemic antitumor immune response which is capable of destroying metastasized cancer cells at distal sites, making oncolytic viruses promising next-generation cancer therapeutics. Additionally, oncolytic viruses in combination with conventional cancer therapeutics (chemo- or radiotherapy) as well as cancer immunotherapeutics can elicit a synergistic antitumor effect.

TOP